E78.2

Mixed hyperlipidemia

Mixed hyperlipidemia, also referred to as combined hyperlipidemia, is a metabolic condition characterized by the concurrent elevation of serum cholesterol and triglyceride levels. This biochemical profile typically involves increased concentrations of low-density lipoprotein (LDL) cholesterol and very-low-density lipoprotein (VLDL) triglycerides, often accompanied by a reduction in high-density lipoprotein (HDL) cholesterol. Pathologically, it is frequently associated with an overproduction of apolipoprotein B-100 in the liver and a decreased clearance of triglyceride-rich lipoprotein remnants. The condition is a primary driver of premature atherosclerotic cardiovascular disease (ASCVD), significantly increasing the risk for myocardial infarction, stroke, and peripheral arterial disease. It encompasses several clinical entities, including Familial Combined Hyperlipidemia (FCHL) and Type III Hyperlipoproteinemia (Dysbetalipoproteinemia), the latter characterized by the accumulation of 'broad-beta' lipoproteins (remnant particles). Clinical management focuses on aggressive lipid-lowering through therapeutic lifestyle changes and pharmacological interventions such as statins, fibrates, or omega-3 fatty acids.

Clinical Symptoms

  • Xanthomas (specifically eruptive xanthomas on the trunk or extremities)
  • Tendinous xanthomas (firm nodules on the Achilles tendon or finger extensor tendons)
  • Palmar xanthomas (yellowish streaks in the creases of the palms, characteristic of Type III)
  • Xanthelasma (yellowish lipid deposits around the eyelids)
  • Arcus senilis (whitish or grayish corneal ring, especially in patients under 45)
  • Abdominal pain (secondary to acute pancreatitis if triglyceride levels exceed 1000 mg/dL)
  • Angina pectoris (chest pain due to early-onset coronary artery disease)
  • Intermittent claudication (pain in the legs during exertion)
  • Eruptive xanthomata (small red-yellow papules occurring in crops)
  • Lipemia retinalis (milky appearance of the retinal vessels)
  • Hepatosplenomegaly (in severe cases of chylomicronemia/VLDL elevation)

Common Causes

  • Familial Combined Hyperlipidemia (genetic mutation affecting lipid transport and metabolism)
  • Type III Hyperlipoproteinemia (Dysbetalipoproteinemia, associated with APOE2/E2 genotype)
  • Excessive dietary intake of saturated fats and refined sugars
  • Obesity and metabolic syndrome
  • Poorly controlled Diabetes Mellitus (type 2)
  • Hypothyroidism
  • Chronic kidney disease (CKD) and nephrotic syndrome
  • Excessive alcohol consumption
  • Medication side effects (e.g., glucocorticoids, thiazide diuretics, non-selective beta-blockers, estrogens)
  • Sedentary lifestyle and lack of physical activity

Documentation & Coding Tips

Explicitly document concurrent elevations of both cholesterol and triglyceride levels to justify the use of the mixed hyperlipidemia code rather than a more generic hyperlipidemia code.

Example: Patient presents for follow-up of lipid management. Recent fasting labs demonstrate a Total Cholesterol of 265 mg/dL, LDL of 168 mg/dL, and Triglycerides of 310 mg/dL. This concurrent elevation in multiple lipid fractions confirms the diagnosis of Mixed Hyperlipidemia (E78.2). Patient has comorbid Type 2 Diabetes Mellitus (E11.9) which contributes to the mixed dyslipidemic profile. Statin therapy continued with the addition of Fenofibrate to target the triglyceride component.

Billing Focus: Confirm that both cholesterol and triglyceride elevations are present in the medical record to support the specificity of E78.2.

Identify the specific phenotype of mixed hyperlipidemia when possible, such as Familial Combined Hyperlipidemia, to enhance diagnostic specificity and support genetic testing or specialized counseling.

Example: Clinical evaluation of 34-year-old male with a family history of premature coronary artery disease. Fasting lipid profile shows LDL 190 mg/dL and Triglycerides 250 mg/dL. Physical exam reveals no xanthomas. Diagnostic findings are consistent with Familial Combined Hyperlipidemia (E78.2). Given the family history and phenotypic presentation, patient is high risk for early atherosclerotic events.

Billing Focus: Specificity of the phenotype supports the medical necessity for advanced lipid testing or genetic consultation codes.

Link mixed hyperlipidemia to associated metabolic conditions such as obesity, metabolic syndrome, or glucose intolerance to provide a complete clinical picture of the patients metabolic health.

Example: 52-year-old female with Metabolic Syndrome (E88.81) and morbid obesity (E66.01, BMI 42). Current lipid panel shows persistent mixed hyperlipidemia (E78.2) with LDL 155 mg/dL and Triglycerides 285 mg/dL despite dietary modifications. The mixed lipid profile is likely exacerbated by insulin resistance and visceral adiposity. Initiating moderate-intensity statin and referring to Medical Nutrition Therapy.

Billing Focus: Linking the diagnosis to comorbidities like obesity or metabolic syndrome supports the use of higher-level E/M codes (99214) due to increased complexity.

Clearly document the therapeutic goals and the patients response to treatment for mixed hyperlipidemia to demonstrate ongoing medical management and decision-making.

Example: Established patient with chronic mixed hyperlipidemia (E78.2). Current regimen of Atorvastatin 40mg and Vascepa 2g BID. Today's labs show LDL improved to 88 mg/dL and TG decreased to 160 mg/dL. Mixed hyperlipidemia is currently stable on dual therapy. Monitored for potential statin-associated muscle symptoms; none reported. Plan to continue current dosages with repeat lipid panel in 6 months.

Billing Focus: Detailed monitoring of therapeutic response justifies the medical necessity for recurring laboratory testing and follow-up visits.

Differentiate between primary mixed hyperlipidemia and secondary causes such as medication side effects or alcohol use to ensure accurate diagnostic sequencing.

Example: Patient presents with new-onset mixed hyperlipidemia (E78.2). Review of systems and history reveals significant daily alcohol consumption and recent initiation of a thiazide diuretic for hypertension (I10). LDL is 170 mg/dL and Triglycerides are 350 mg/dL. Discussed that the mixed lipid profile may be secondary to lifestyle factors and medication interactions. Recommended alcohol cessation and will consider alternative antihypertensive therapy before escalating lipid-lowering medications.

Billing Focus: Documentation of secondary causes provides the clinical rationale for lifestyle interventions and medication changes prior to starting chronic statin therapy.

Relevant CPT Codes

Related Diagnoses

Hierarchy